ArticleClinical, cosmetic and investigational dermatology2025
Human Fibroblast Growth Factor 9 Induces Hair Follicle Cycle Transition via TGF-β/BMP/Smad Pathway.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond scarring: immune-epithelial crosstalk in wound-induced hair follicle neogenesis.Frontiers in immunology · 2026Review
- Recent Advances in the Role of Fibroblast Growth Factors in Hair Follicle Growth.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibroblast growth factor 9 (FGF9) is a crucial regulator of hair follicle development; however, the precise regulatory role of FGF9 on the biological behavior of hair follicles remains unclear. Purpose: Explore the effects of recombinant human fibroblast growth factor (rhFGF9) on hair follicle growth and cycle transition in mice, as well as the associated mechanisms. Methods: We utilized soluble recombinant human fibroblast growth factor 9 (rhFGF9), expressed in Escherichia coli, and injected it into the dorsal skin of mice. RNA sequencing (RNA-seq) was employed to identify differentially expressed genes and associated key metabolic pathways in skin tissue. Additionally, immunohistochemistry, quantitative PCR (qPCR), and Western blotting techniques were applied to assess the expression of factors related to metabolic pathways across different groups. Results: RhFGF9 stimulated hair growth by inducing the anagen phase in C57BL/6 N mice. Histological analysis revealed that intradermal injections of rhFGF9 enhanced hair follicle development. Transcriptomic analysis revealed that the mechanism underlying this effect might involve the transforming growth factor-β (TGF-β) signaling pathway. Immunohistochemistry, quantitative PCR, and Western blot analyses further demonstrated the upregulation of TGF-β2, TGF-β3, bone morphogenetic protein 4 (BMP4), and pSmad2 expression in the experimental group. Conclusion: These results indicate that rhFGF9 might promote hair growth via the TGF-β/BMP/Smad signaling pathway and highlight its potential as a therapeutic option for treating hair loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.